

## 4. Nano-pharmaceuticals

### Prelims: Science & Technology Mains: GS-III Science & Technology

#### Why in News?

▶ The Ministry of Health and Family Welfare released guidelines for evaluation of nanopharmaceuticals, which are emerging as more potent tools for treating various diseases.

#### What are Nano-Pharmaceuticals?

- Nanopharmaceuticals represent an emerging field where the sizes of the drug particle or a therapeutic delivery system work at the nanoscale.
- >> They are derived by application of nanotechnology in medical therapeutics.
- ▶ In the pharmaceutical industry, a long-standing issue is a difficulty of delivering the appropriate dose of a particular active agent to specific disease site.
- ➤ Nanopharmaceuticals have enormous potential in addressing this failure of traditional therapeutics which offers site-specific targeting of active agents.
- Such precision targeting via nanopharmaceuticals reduces toxic systemic side effects, resulting in better patient compliance.

#### **Benefits:**

- ➤ They are expected to bring about a revolution in treatment strategies as they would enable targeting specific delivery of drugs and therapeutic molecules.
- >> They offer higher efficacy and lower toxicity in many disease conditions.
- >> They are expected to be of great use particularly in cancer treatment.

#### Why Need Guidelines?

- Every year several new nano-pharmaceuticals are being developed and marketed across the world.
- ▶ India too has a sizable pool of nano-scientists generating a large number of scientific publications in this domain.
- ▶ However, regulatory approval is the most important factor for translating laboratory research into bedside medicine.
- ▶ The new set of guidelines is designed to facilitate this process.

#### **Guidelines:**

➤ The guidelines cover all the aspects of evaluation from the definition and categorization of nano-pharmaceuticals to pharmacovigilance of the new set of therapeutics.



# DAILY CURRENT AFFAIRS October 30<sup>th</sup> 2019

- ▶ It has been prepared as a joint project by the Department of Biotechnology (DBT) in the Union Ministry of Science and Technology, and ICMR and Central Drugs Standard Control Organisation under health Ministry.
- ▶ It will give a big boost to innovators and drug manufacturers to optimise their research and come out with medicines that would be safer and more affordable.

